The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545) , is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third SERD clinical candidate from Genentech (after GDC-0810 and GDC-0927) and a number of oral SERDs have previously [...]
< 1 minute read
Feb. 9, 2022
Giredestrant (GDC-9545): an Oral Selective Estrogen Receptor Degrader and Full Antagonist
Genentech ER Degrader
selective ER degrader (SERD) + full antag. oral (30 mg QD), Ph. III for ER+, HER2- BC from profiling >4k cmpds for desired MoA giredestrant (GDC-9545) Genentech, South San Francisco, CA